FWBI Key Statistics, Chart & Performance
The current stock price of FWBI is 2.96 USD. In the past month the price increased by 4.23%. In the past year, price decreased by -93.21%.
FWBI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About FWBI
Company Profile
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
Company Info
FIRST WAVE BIOPHARMA
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
CEO: James Sapirstein
Employees: 10
Phone: 15615897020
FIRST WAVE BIOPHARMA / FWBI FAQ
What does FIRST WAVE BIOPHARMA do?
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
What is the stock price of FIRST WAVE BIOPHARMA today?
The current stock price of FWBI is 2.96 USD. The price increased by 4.59% in the last trading session.
Does FWBI stock pay dividends?
FWBI does not pay a dividend.
How is the ChartMill rating for FIRST WAVE BIOPHARMA?
FWBI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of FIRST WAVE BIOPHARMA (FWBI)?
FIRST WAVE BIOPHARMA (FWBI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-88.75).
What is FIRST WAVE BIOPHARMA worth?
FIRST WAVE BIOPHARMA (FWBI) has a market capitalization of 4.62M USD. This makes FWBI a Nano Cap stock.
What is the next earnings date for FWBI stock?
FIRST WAVE BIOPHARMA (FWBI) will report earnings on 2024-08-14, before the market open.
FWBI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FWBI. When comparing the yearly performance of all stocks, FWBI is a bad performer in the overall market: 98.3% of all stocks are doing better.
FWBI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to FWBI. FWBI has a bad profitability rating. Also its financial health evaluation is rather negative.
FWBI Financial Highlights
Over the last trailing twelve months FWBI reported a non-GAAP Earnings per Share(EPS) of -88.75. The EPS increased by 75.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233.87% | ||
| ROE | -446.8% | ||
| Debt/Equity | 0.17 |
FWBI Forecast & Estimates
8 analysts have analysed FWBI and the average price target is 36.72 USD. This implies a price increase of 1140.54% is expected in the next year compared to the current price of 2.96.